Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism

por Riedl, Marc
Publicado 2010

Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema

por Riedl, Marc
Publicado 2015

Introduction: New Perspectives in Hereditary Angioedema (HAE): Molecular Mechanisms & Therapeutic Choices: A CME Symposium Presented at...

por Zuraw, Bruce L, Frank, Michael M, Riedl, Marc A
Publicado 2010

Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age

por Hsu, Florence Ida, Lumry, William, Riedl, Marc, Tachdjian, Raffi
Publicado 2022

Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age

por Hsu, Florence Ida, Lumry, William, Riedl, Marc, Tachdjian, Raffi
Publicado 2022

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study

por Yang, William, Hébert, Jacques, Ritchie, Bruce, Baptista, Jovanna, Riedl, Marc, Lumry, William R
Publicado 2014

Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain

por Staller, Kyle, Lembo, Anthony, Banerji, Aleena, Bernstein, Jonathan A., Shah, Eric D., Riedl, Marc A.
Publicado 2022

Validation of a suspicion index to identify patients at risk for hereditary angioedema

por Shams, Marissa, Laney, Dawn A., Jacob, Dave A., Yang, Jingjing, Dronen, Jessica, Logue, Amanda, Rosen, Ami, Riedl, Marc
Publicado 2022

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks

por Reshef, Avner, Riedl, Marc, Moldovan, Dumitru, Lockey, Richard F., Montinaro, Vincenzo, Suez, Daniel, Relan, Anurag, Cicardi, Marco, Zuraw, Bruce
Publicado 2012

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

por Busse, Paula J., Farkas, Henriette, Banerji, Aleena, Lumry, William R., Longhurst, Hilary J., Sexton, Daniel J., Riedl, Marc A.
Publicado 2018

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

por Johnston, Douglas T., Busse, Paula J., Riedl, Marc A., Maurer, Marcus, Anderson, John, Nurse, Christina, Inhaber, Neil, Yu, Ming, Banerji, Aleena
Publicado 2021

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

por Levy, Donald S., Farkas, Henriette, Riedl, Marc A., Hsu, Florence Ida, Brooks, Joel P., Cicardi, Marco, Feuersenger, Henrike, Pragst, Ingo, Reshef, Avner
Publicado 2020

Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report

por Bork, Konrad, Anderson, John T., Caballero, Teresa, Craig, Timothy, Johnston, Douglas T., Li, H. Henry, Longhurst, Hilary J., Radojicic, Cristine, Riedl, Marc A.
Publicado 2021

Refractory Status Epilepticus Associated With a Pathogenic Variant in TNFRSF13B

por Yang, Jennifer H, Scanlon, Nicholas, Woo, Wonhee, LaBuzetta, Jamie N, Gonzalez, Cynthia, Broderick, Lori, Doherty, Taylor, Riedl, Marc, Dunn-Pirio, Anastasie
Publicado 2023

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States

por Riedl, Marc A, Banerji, Aleena, Manning, Michael E, Burrell, Earl, Joshi, Namita, Patel, Dipen, Machnig, Thomas, Tai, Ming-Hui, Watson, Douglas J
Publicado 2018

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks

por Riedl, Marc A., Maurer, Marcus, Bernstein, Jonathan A., Banerji, Aleena, Longhurst, Hilary J., Li, H. Henry, Lu, Peng, Hao, James, Juethner, Salomé, Lumry, William R.
Publicado 2020

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

por Lumry, William R., Weller, Karsten, Magerl, Markus, Banerji, Aleena, Longhurst, Hilary J., Riedl, Marc A., Lewis, Hannah B., Lu, Peng, Devercelli, Giovanna, Jain, Gagan, Maurer, Marcus
Publicado 2020

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study

por Banerji, Aleena, Bernstein, Jonathan A., Johnston, Douglas T., Lumry, William R., Magerl, Markus, Maurer, Marcus, Martinez‐Saguer, Inmaculada, Zanichelli, Andrea, Hao, James, Inhaber, Neil, Yu, Ming, Riedl, Marc A.
Publicado 2021

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension

por Riedl, Marc A., Bernstein, Jonathan A., Craig, Timothy, Banerji, Aleena, Magerl, Markus, Cicardi, Marco, Longhurst, Hilary J., Shennak, Mustafa M., Yang, William H., Schranz, Jennifer, Baptista, Jovanna, Busse, Paula J.
Publicado 2017

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

por Cohn, Danny M., Aygören‐Pürsün, Emel, Bernstein, Jonathan A., Farkas, Henriette, Lumry, William R., Maurer, Marcus, Zanichelli, Andrea, Iverson, Matthew, Hao, James, Smith, Michael D., Yea, Christopher M., Audhya, Paul K., Riedl, Marc A.
Publicado 2023